The comorbidities framework defines comorbidity PK/PD determinants as mechanistic processes that shape drug exposure and concentration–effect behavior across multiple physiological conditions. Effectiveness is used only as a pharmacodynamic construct describing concentration-dependent pathway engagement, not as a clinical outcome. In the comparison overview, sildenafil and vardenafil can be distinguished through their concentration-time trajectories and downstream pharmacodynamic coupling. PK determinants include absorption, distribution, metabolism, elimination, and half life, which together shape rising, peak, and declining exposure. Their pk differences can alter exposure geometry across physiological contexts. At the PD level, pd differences concern PDE5 interaction, NO–cGMP signaling, smooth-muscle relaxation, and condition-specific pathway modulation. These processes generate mechanistic onset speed and duration length patterns, while variability, interindividual variability, and clinical variability describe spread without implying outcomes.
Across comorbidities, exposure geometry can be represented as the combined result of systemic input, compartmental distribution, biotransformation, and drug removal. Absorption establishes the rate and extent of systemic entry, while distribution controls movement between plasma and tissue compartments. Metabolism contributes to transformation and concentration decline, while elimination determines removal from the relevant systemic pool. Half life summarizes one aspect of concentration decay without defining the entire pharmacodynamic window. The resulting pk differences between sildenafil and vardenafil can appear as changes in rise rate, peak geometry, distributional behavior, or declining exposure. These concentration trajectories become inputs to pd differences, where PDE5 inhibition changes cGMP handling and NO–cGMP signaling. Smooth-muscle relaxation represents a downstream pathway state, while individual comorbidities can provide condition-specific modulation of vascular, metabolic, inflammatory, neurological, or tissue signaling. Thus onset speed and duration length describe temporal regions of a coupled PK/PD trajectory rather than clinical endpoints.
The concentration–effect relationship provides the bridge between exposure and downstream pathway geometry across comorbidity states. As sildenafil or vardenafil concentration rises, PDE5 interaction can increase according to the relevant pharmacodynamic relationship, reducing PDE5-mediated cGMP degradation and changing the modeled NO–cGMP signal. Smooth-muscle relaxation is represented downstream, while condition-specific physiological pathways can provide additional modulation around the core PDE5 mechanism. Effectiveness therefore refers only to the degree of concentration-dependent pathway engagement and does not describe clinical success. Differences in pk differences alter the concentration input, whereas pd differences describe downstream mapping. Distribution can affect tissue exposure timing, and elimination shapes concentration decline. Onset speed represents the ascending exposure and concentration–effect transition, while duration length represents persistence during declining exposure. Variability can increase when several comorbidity-related PK and PD parameters differ simultaneously. Interindividual variability and clinical variability describe heterogeneity in these mechanistic trajectories without converting them into outcome claims.
Comorbidity-related PK/PD foundations begin by separating exposure geometry from downstream concentration–effect behavior. Within comorbidities, physiological conditions are represented as contexts that may modify individual PK or PD parameters rather than as one universal pharmacological shift. Pk differences describe how sildenafil and vardenafil can generate distinct concentration-time trajectories through differences in systemic input, distribution, metabolism, and elimination. Absorption establishes the early systemic input, while distribution controls movement between circulating and tissue compartments. The resulting concentration curve becomes the input to the PD system. Pd differences describe how concentration is converted into PDE5 inhibition, altered cGMP handling, and downstream NO–cGMP pathway engagement. Smooth-muscle relaxation represents a downstream signaling state, while the particular comorbidity context can add condition-specific modulation. Thus exposure geometry and concentration–effect geometry remain conceptually distinct: PK determines concentration over time, whereas PD determines pathway state generated by that concentration within a given physiological context.
Exposure geometry across comorbidities can be decomposed into systemic input, compartmental movement, and concentration decline. Absorption determines how rapidly drug enters systemic circulation and therefore shapes the ascending region of the exposure curve. Distribution introduces movement between central and peripheral compartments, which can alter tissue availability and apparent persistence. Pk differences between sildenafil and vardenafil can therefore appear as differences in rise rate, peak region, or declining exposure. Within comorbidities, these differences are interpreted as changes in the concentration input rather than as outcome differences. Pd differences describe how that concentration interacts with PDE5 and changes the NO–cGMP pathway. A particular comorbidity can introduce additional modulation through vascular, metabolic, inflammatory, neurological, or tissue-specific signaling pathways. The resulting concentration–effect geometry is therefore multidimensional: the PK trajectory determines when concentration changes occur, while the PD system determines how those changes are translated into pathway engagement.
Mechanistic effectiveness refers only to concentration-dependent engagement of a defined pharmacodynamic pathway. In comorbidities, sildenafil and vardenafil can be represented as distinct exposure trajectories entering a shared PDE5-centered architecture. Pk differences alter the time-dependent concentration signal, while pd differences describe the relationship between concentration and PDE5 pathway engagement. Absorption primarily shapes the early ascending segment, whereas distribution contributes to compartmental equilibration and tissue exposure. Condition-specific physiology can modify the surrounding signaling environment without replacing PDE5 inhibition as the direct pharmacological interaction. As concentration rises, the modeled PDE5-linked state can transition upward; as concentration falls, pathway engagement can progressively decline. The same general PK/PD architecture can therefore produce different geometries when parameter values differ across comorbidities. This framework remains descriptive: exposure establishes the concentration signal, PDE5 interaction translates concentration into pathway engagement, and condition-specific physiology provides additional mechanistic context without being treated as a clinical outcome.
Comorbidity-related PK determinants describe the processes that establish sildenafil or vardenafil exposure across diverse physiological conditions. Absorption determines the rate and extent of systemic entry and therefore shapes the ascending concentration curve. Distribution controls movement between plasma and tissue compartments and can modify the relationship between circulating concentration and tissue availability. Metabolism contributes to biotransformation and concentration loss, while elimination represents the broader processes responsible for drug removal. These parameters interact rather than functioning independently. A comorbidity-related change in absorption can shift early exposure without necessarily producing an equivalent change in total exposure. Distribution can alter compartmental concentration relationships, while metabolism and elimination primarily shape the declining limb and persistence of exposure. Across comorbidities, different physiological states can therefore produce different combinations of PK parameter changes. The resulting exposure geometry supplies the concentration signal for downstream PDE5 pharmacodynamics. This distinction keeps PK interpretation separate from clinical effectiveness and allows each comorbidity-related mechanism to be described according to its position within the concentration-time trajectory.
The exposure curve reflects the combined effects of input, compartmental movement, and drug removal. Absorption contributes the input function and determines how rapidly systemic concentration rises. Distribution introduces movement between central and peripheral compartments, influencing tissue equilibration and apparent plasma exposure. Metabolism contributes to concentration loss through enzymatic transformation, while elimination integrates processes that remove drug from the relevant systemic pool. In comorbidities, these determinants should be considered as potentially variable parameters rather than assumed to change in one universal direction. A physiological condition may influence one pathway while leaving another comparatively unchanged. Sildenafil and vardenafil can consequently occupy distinct exposure geometries even when the broad PK sequence remains identical. The resulting concentration-time signal becomes the input to PDE5 interaction and NO–cGMP pathway modeling. PK therefore establishes the geometry of exposure, while PD determines how the resulting concentration is translated into downstream pathway engagement within the corresponding physiological context.
Sildenafil and vardenafil can be represented using the same broad sequence of absorption, distribution, metabolism, and elimination while retaining different parameter values. Absorption differences influence the timing of early systemic exposure, distribution differences alter compartmental equilibration, metabolism changes the transformation rate, and elimination determines the resulting concentration decline. Across comorbidities, these parameters can become more heterogeneous because different physiological conditions affect different components of drug handling. The resulting geometry may show altered rise rate, peak shape, decline slope, or persistence. Such changes are PK descriptions rather than outcome statements. Once established, the concentration trajectory becomes the time-dependent input to PDE5 inhibition. The downstream NO–cGMP pathway then responds according to the pharmacodynamic concentration relationship, while condition-specific physiological signaling can provide additional modulation. This separation permits exposure geometry to be analyzed independently from concentration–effect behavior and avoids treating any particular comorbidity-related PK configuration as a direct measure of clinical effectiveness.
| Comorbidity Determinant | PK Basis | Role in Exposure Geometry |
|---|---|---|
| Absorption | Rate and extent of systemic drug entry | Shapes the ascending concentration limb and timing of early exposure. |
| Distribution | Movement between plasma and tissue compartments | Modifies compartmental concentration gradients and tissue equilibration. |
| Metabolism | Enzymatic transformation of parent drug | Contributes to concentration decline and curvature of the elimination phase. |
| Elimination | Removal through metabolic and systemic clearance processes | Determines the rate at which systemic exposure decreases. |
| Condition-related PK modulation | Physiological changes affecting one or more PK parameters | Can broaden or shift rise, peak, decline, or persistence geometry. |
Comorbidity-related PD determinants describe how sildenafil and vardenafil concentrations are translated into pathway states across differing physiological contexts. Pd differences center on concentration-dependent PDE5 interaction. Inhibition of PDE5 reduces cGMP degradation and changes the modeled NO–cGMP signaling state as drug concentration changes. Effectiveness is used only to describe the degree of defined pathway engagement at a particular concentration and time. Distribution can influence the timing relationship between plasma exposure and tissue availability, while elimination determines how the concentration input declines. Duration length can therefore be represented as persistence of concentration-linked pathway engagement during declining exposure. Across comorbidities, condition-specific modulation may influence vascular tone, smooth-muscle signaling, inflammatory pathways, autonomic signaling, or tissue physiology. These pathways form contextual layers around the direct PDE5 mechanism. The resulting PD model is therefore a coupled representation of drug concentration, PDE5 inhibition, NO–cGMP signaling, and physiological context rather than a single outcome variable.
The concentration–effect mapping can be represented as a sequence from inhibitor concentration to PDE5 interaction, altered cGMP availability, and downstream smooth-muscle signaling. Pd differences describe this mapping without assigning a clinical result. Effectiveness therefore means modeled pathway engagement rather than treatment success. Distribution influences the relationship between systemic concentration and tissue compartment exposure, while elimination determines how rapidly the concentration stimulus declines. As concentration rises, PDE5 inhibition can increase according to the pharmacodynamic relationship. As concentration falls, the degree of inhibition can progressively decrease, changing the downstream NO–cGMP state. Duration length thus reflects persistence of the modeled concentration-linked pathway state rather than a clinical duration claim. Different comorbidities can add condition-specific pathway modulation around this core sequence, potentially affecting the signaling environment in which smooth-muscle relaxation is represented. The direction and magnitude of such modulation remain dependent on the particular physiological mechanism rather than on the comorbidity label alone.
Sildenafil and vardenafil can be compared mechanistically by separating concentration trajectories from downstream pathway mappings. Pd differences describe the concentration-to-PDE5 relationship, while effectiveness describes the degree of defined pharmacodynamic pathway engagement. Distribution can modify the timing between plasma concentration and tissue exposure, and elimination shapes the declining concentration signal. PDE5 inhibition changes cGMP degradation and influences the NO–cGMP pathway, with smooth-muscle relaxation represented downstream. Duration length emerges from persistence of the concentration input and corresponding pathway state. Condition-specific modulation can then be represented as an additional layer affecting vascular, inflammatory, neurological, metabolic, or tissue signaling. The combined model is multidimensional: PK establishes concentration over time, PDE5 interaction translates concentration into pathway engagement, and comorbidity-related physiology modifies the surrounding signaling environment. This framework permits concentration–effect transitions to be described neutrally without turning pathway geometry into a statement about real-world effectiveness or clinical outcomes.
Half-life and clearance describe related but distinct properties of declining exposure. Half life summarizes concentration decay under defined kinetic conditions, while elimination represents processes responsible for removing drug from the relevant systemic pool. Metabolism contributes to elimination through enzymatic transformation, while total clearance reflects the combined removal processes. Across comorbidities, physiological changes can modify selected clearance or distribution parameters when the relevant mechanism affects drug handling. Pk differences between sildenafil and vardenafil can consequently appear as differences in clearance, distribution-linked persistence, or the shape of the declining concentration curve. A slower decline maintains the concentration signal for a longer modeled interval, while a faster decline reduces it more rapidly. Half-life alone does not define the complete concentration–effect window because distribution, PDE5 interaction, downstream signaling, and pathway recovery also contribute. The mechanistic interpretation therefore treats half-life as one descriptor within a broader exposure geometry rather than as an independent measure of pharmacodynamic duration.
Exposure persistence represents the time-dependent availability of drug concentration as an input to the pharmacodynamic system. Elimination determines how rapidly that input decreases, while metabolism contributes to transformation and removal of parent drug. Half life provides a compact descriptor of selected concentration-decay behavior but does not specify the complete concentration–effect trajectory. Pk differences can produce different declining limbs for sildenafil and vardenafil because their clearance and distribution characteristics differ. Across comorbidities, additional PK spread can occur when physiological conditions modify relevant clearance parameters. The resulting concentration trajectory determines the time-dependent input to PDE5 interaction. As concentration falls, PDE5 inhibition changes, followed by corresponding changes in cGMP handling and NO–cGMP pathway state. Exposure persistence therefore provides the PK basis for interpreting temporal PD transitions, while condition-specific physiological modulation remains a separate contextual component. This framework does not equate half-life with clinical duration or convert exposure persistence into a clinical effectiveness claim.
Clearance-related geometry can contain distribution-linked phases that make the declining trajectory more complex than a single slope. Metabolism can contribute to multiple portions of concentration decline depending on the kinetic model, while elimination integrates the relevant removal processes. Half life summarizes one aspect of decay without specifying tissue redistribution or the complete persistence of pathway engagement. Pk differences between sildenafil and vardenafil can therefore appear through differences in decline rate, curvature, or exposure persistence. Across comorbidities, these differences can coexist with condition-specific changes in physiological signaling without requiring a uniform pharmacokinetic shift. The concentration trajectory remains the direct input to PDE5 interaction. Changes in PDE5 inhibition alter cGMP degradation and the NO–cGMP pathway state, while smooth-muscle and condition-specific signaling provide downstream context. The resulting temporal geometry is therefore a composite of clearance, distribution, concentration–effect coupling, and physiological modulation. No single half-life value independently determines the full pathway trajectory.
| Clearance Component | PK Basis | Interpretation |
|---|---|---|
| Metabolic clearance | Enzymatic transformation of parent drug | Contributes to the rate of parent-drug concentration decline. |
| Systemic elimination | Removal of drug from the relevant systemic pool | Determines the overall direction and rate of exposure loss. |
| Distribution-linked return | Exchange between peripheral and central compartments | Can modify apparent terminal decline and exposure persistence. |
| Clearance variability | Differences in metabolic or physiological clearance parameters | Broadens the range of possible concentration-decay trajectories. |
| Half-life relationship | Concentration decay determined by clearance and distribution characteristics | Summarizes selected decay behavior rather than the complete pharmacodynamic window. |
Variability across comorbidities can be represented as spread across the PK and PD parameters controlling exposure and pathway engagement. Variability may arise from differences in absorption, distribution, metabolism, elimination, tissue equilibration, PDE5 sensitivity, NO–cGMP coupling, smooth-muscle signaling, and condition-specific physiological modulation. Interindividual variability describes differences between parameter sets, while clinical variability is used only as a descriptive category for heterogeneous response-related patterns. Within comorbidities, different physiological conditions can introduce different combinations of PK and PD variation. One condition may primarily affect systemic clearance, another may influence tissue distribution, while another may modify vascular or inflammatory signaling. Sildenafil and vardenafil can consequently occupy different regions of a multidimensional PK/PD parameter space. The resulting concentration-time profiles may differ in rise rate, peak geometry, decline slope, or persistence. The downstream concentration–effect mappings may also differ. Variability therefore describes the spread of mechanistic trajectories without implying a clinical outcome, comparative ranking, or real-world effectiveness.
PK variability changes the concentration-time input, whereas PD variability changes how concentration is translated into pathway engagement. Variability in absorption can shift the ascending limb, while distribution differences can alter compartmental equilibration. Metabolic and elimination differences can modify the declining limb, and pharmacodynamic differences can change the concentration-to-PDE5 relationship. Interindividual variability can therefore broaden both exposure geometry and concentration–effect mapping. Clinical variability remains a descriptive category and does not itself establish an outcome. Across comorbidities, condition-specific signaling can add another layer by modifying the physiological environment around NO–cGMP and smooth-muscle pathways. These mechanisms need not change in the same direction. A PK parameter may shift concentration timing while a separate PD parameter changes pathway sensitivity. The resulting system is therefore better represented as a distribution of coupled PK/PD states than as one fixed trajectory. Sildenafil and vardenafil remain distinguishable through their underlying exposure and concentration–effect relationships.
Mechanistic timing describes the temporal relationship among exposure formation, concentration-dependent PDE5 interaction, downstream signaling, and exposure decline. Variability in absorption can alter the early concentration trajectory, while distribution can change tissue equilibration. Metabolism and elimination can shift the declining phase, while PD sensitivity and condition-specific modulation can alter concentration–effect transitions. Interindividual variability captures differences among these parameter combinations, and clinical variability describes heterogeneity without assigning a specific cause or outcome. Across comorbidities, multiple physiological contexts can therefore generate distinct timing geometries. Sildenafil and vardenafil can be represented as separate exposure trajectories entering related PDE5-centered pharmacodynamic systems. The concentration signal determines the time-dependent degree of PDE5 engagement, while the surrounding physiological condition modifies additional signaling pathways. This produces a coupled timing model in which onset-related concentration rise, peak-region behavior, pathway engagement, and declining exposure can vary across parameter sets. The framework remains mechanistic and descriptive rather than outcome-oriented.
Comorbidity-related PK determinants are the mechanisms that shape sildenafil or vardenafil exposure across different physiological conditions. They include absorption, distribution, metabolism, and elimination. Absorption determines the rate and extent of systemic entry and therefore influences the ascending concentration curve. Distribution governs movement between plasma and tissue compartments and can change compartmental concentration relationships. Metabolism contributes to enzymatic transformation and concentration loss, while elimination represents the broader removal of drug from the relevant systemic pool. Different comorbidities can influence different PK parameters, and the effects do not necessarily move in one common direction. The resulting exposure geometry can therefore differ across physiological states. This concentration-time trajectory becomes the input to the pharmacodynamic system. The construct describes drug handling mechanistically and does not represent a clinical outcome or real-world effectiveness measure.
Comorbidity-related PD determinants describe how sildenafil or vardenafil concentration is translated into pathway states across different physiological contexts. The central direct mechanism is PDE5 interaction. Inhibition of PDE5 reduces cGMP degradation and changes the NO–cGMP signaling state in a concentration-dependent manner. Smooth-muscle relaxation is represented as a downstream signaling process. A particular comorbidity can add condition-specific modulation involving vascular, inflammatory, metabolic, neurological, autonomic, or tissue pathways. These contextual mechanisms can alter the environment surrounding PDE5-linked signaling without replacing PDE5 as the direct pharmacological target. PD determinants therefore include concentration-dependent PDE5 engagement, downstream cGMP behavior, NO–cGMP coupling, smooth-muscle signaling, and condition-specific pathway modulation. They describe pharmacodynamic pathway geometry rather than clinical success, treatment response, or real-world effectiveness. The framework remains focused on concentration-dependent physiological mechanisms.
Exposure geometry describes the shape and timing of the sildenafil or vardenafil concentration-time trajectory. It includes the rate of concentration rise, peak region, compartmental distribution, and subsequent decline. Absorption establishes systemic input, distribution modifies movement between plasma and tissue compartments, and metabolism and elimination shape concentration loss. Across comorbidities, different physiological conditions can alter selected PK parameters, creating different combinations of rise rate, peak shape, and exposure persistence. No single direction of change is implied by the general category of comorbidity. The resulting concentration trajectory becomes the input to the pharmacodynamic system. Exposure geometry is therefore a PK construct that describes concentration over time. It does not directly describe clinical effectiveness. Differences between sildenafil and vardenafil can be represented as differences in the parameters governing this trajectory while retaining the same broad sequence of absorption, distribution, metabolism, and elimination.
Concentration–effect mapping represents the relationship between sildenafil or vardenafil concentration and PDE5 pathway engagement. As inhibitor concentration rises, PDE5 inhibition can increase according to the relevant pharmacodynamic relationship. Reduced PDE5-mediated cGMP degradation then changes the NO–cGMP signaling state, with smooth-muscle relaxation represented downstream. A comorbidity can add condition-specific physiological modulation around this core mechanism. The concentration signal is supplied by the PK trajectory, while the concentration–effect function translates that signal into a modeled pathway state. As concentration declines, PDE5 inhibition can progressively decrease and downstream signaling can transition toward lower exposure. Mechanistic effectiveness refers only to the degree of defined pathway engagement at a particular concentration and time. It does not mean clinical benefit, treatment success, or another clinical outcome. The model therefore keeps exposure, pharmacodynamic mapping, and condition-specific modulation conceptually separate.
Half-life is a pharmacokinetic descriptor of concentration decay under defined kinetic conditions. It reflects how rapidly concentration decreases over a specified portion of an exposure trajectory, but it does not independently define the full persistence of PDE5 pathway engagement. Clearance and distribution characteristics contribute to half-life, and compartmental exchange can produce more complex decline patterns than a single exponential process. Across comorbidities, physiological changes can modify selected PK parameters when the relevant mechanisms affect drug handling. The direction and magnitude of such changes depend on the specific pathway rather than on the comorbidity category alone. Sildenafil and vardenafil can therefore show different relationships among half-life, clearance, distribution, and overall exposure persistence. Half-life should be interpreted as one component of PK geometry rather than as a complete duration measure. It does not directly establish pharmacodynamic effectiveness or any clinical outcome.
Distribution describes movement of drug between circulating plasma and peripheral tissue compartments. Changes in tissue composition, perfusion, protein binding, compartmental exchange, or physiological state can modify distribution parameters when those mechanisms affect drug partitioning. Different comorbidities can alter these variables to different degrees, so no single distributional pattern applies across all conditions. Distribution can influence plasma concentration, tissue exposure, equilibration time, and the apparent shape of the concentration-time curve. For sildenafil and vardenafil, differences in distribution can modify the temporal relationship between systemic concentration and tissue concentration relevant to PDE5 pathway engagement. These effects interact with absorption, metabolism, and elimination rather than operating independently. The resulting mechanistic consequence is altered exposure geometry and compartmental timing. Distribution changes do not by themselves establish clinical effectiveness, treatment response, or a comparative outcome.
Metabolism is the enzymatic transformation of drug molecules and can form an important component of systemic clearance. Across comorbidities, metabolic behavior can vary when physiological changes affect enzyme activity, hepatic handling, competing pathways, or related systemic processes. The direction and magnitude of any change depend on the specific mechanism rather than on the diagnosis category alone. A change in metabolic rate can modify concentration decline, exposure persistence, or the relationship between early and later portions of the concentration trajectory. Sildenafil and vardenafil can have different metabolic characteristics, so their exposure geometries may respond differently to the same physiological context. Metabolism should not be considered separately from absorption, distribution, and elimination because all four contribute to exposure formation. The resulting concentration-time profile becomes the input to PDE5 pharmacodynamics. The mechanistic consequence is altered exposure geometry, not a direct statement about clinical effectiveness.
Elimination represents the processes through which drug leaves the relevant systemic pool. It includes metabolic clearance and other routes of removal, with relative contributions depending on the compound and physiological state. Across comorbidities, elimination can vary when systemic, hepatic, renal, metabolic, or tissue-related mechanisms alter clearance parameters. A change in effective clearance can modify the slope of concentration decline, but the resulting exposure trajectory also depends on distribution and ongoing systemic input. Sildenafil and vardenafil can therefore produce different declining exposure geometries because their clearance and distribution characteristics differ. Elimination determines how quickly the concentration signal available to the pharmacodynamic system diminishes. As concentration falls, PDE5 inhibition and the associated NO–cGMP pathway state can progressively change. The mechanistic interpretation concerns concentration decay and exposure persistence. It does not imply a clinical duration, treatment outcome, or real-world effectiveness.
Variability can increase when several PK and PD parameters differ across physiological conditions. On the PK side, absorption, distribution, metabolism, clearance, protein binding, and tissue equilibration can broaden the range of concentration-time profiles. On the PD side, PDE5 sensitivity, NO–cGMP coupling, smooth-muscle signaling, and condition-specific pathway modulation can broaden the concentration–effect relationship. Different comorbidities can affect different subsets of these parameters, creating heterogeneous combinations rather than one common change. One parameter may shift the concentration trajectory while another modifies how concentration is translated into PDE5 pathway engagement. The resulting system is therefore a distribution of coupled PK/PD states rather than a single deterministic curve. Variability describes this mechanistic spread. It does not establish clinical effectiveness, comparative superiority, or treatment outcome. The same framework can be used to compare sildenafil and vardenafil while keeping PK differences and PD differences conceptually distinct.
Mechanistic timing describes the temporal relationship among exposure formation, concentration-dependent PDE5 interaction, downstream signaling, and concentration decline. The early region is shaped by systemic input and absorption, followed by distribution and rising concentration. As concentration increases, PDE5 inhibition can change and alter cGMP handling within the NO–cGMP pathway. Smooth-muscle signaling represents a downstream component, while condition-specific physiology provides additional context. During the declining phase, metabolism, elimination, and distribution-linked processes reduce the concentration input, allowing PDE5 pathway engagement to change accordingly. Different comorbidities can modify one or more of these parameters, producing distinct timing geometries. Sildenafil and vardenafil can therefore be represented as different PK/PD trajectories within a shared mechanistic architecture. Mechanistic timing is not a clinical recommendation or outcome prediction. It is a descriptive framework linking concentration over time with PDE5 interaction, downstream signaling, and condition-specific physiological modulation.